3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Hematologic Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Leukemia, Myeloid, Acute
2
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Glioma
1
Breast Neoplasms
1
Brain Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
entrectinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled